A Study of the Safety and Efficacy of CMX001 for the Prevention of CMV Infection in CMV-seropositive HCT Recipients
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
This randomized, double-blind, placebo-controlled, parallel group, multicenter study compared
the effectiveness of oral brincidofovir (BCV) to placebo for the prevention of
cytomegalovirus (CMV) infection in stem cell transplant patients who were CMV seropositive
but negative for CMV viremia before starting treatment with BCV.